DGX News

Guardant Health and Quest Diagnostics Announce Strategic Collaboration to Broaden Access to Guardant’s Shield™ Blood-based Screening Test in the United States

DGX

PALO ALTO, Calif. & SECAUCUS, N.J.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced a broad strategic collaboration to make Guardant’s Shield™ blood-based screening test available to physicians and patients served by Quest in the United States. Shield is the first and only blood test to receive full FDA approval as a primary screening option for colorectal c

September 24, 2025
Read more →

Quest Diagnostics Launches Advanced Pharmacogenomics (PGx) Offering

DGX

(NYSE:DGX) New Service Empowers Clinicians with Personalized Insights from Coriell Life Sciences to Optimize Prescribing Across Specialties SECAUCUS, N.J., Sept. 4, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced an advanced...

September 4, 2025Diagnostics
Read more →

Fentanyl Positivity Is More Than Seven Times Higher in Random Tests vs. Pre-Employment Drug Screening, Finds 2025 Quest Diagnostics Drug Testing Index

DGX

(NYSE:DGX) Majority of fentanyl positives also contain other drugs, with co-positivity with marijuana doubling since 2020 SECAUCUS, N.J., Sept. 2, 2025 /PRNewswire/ -- The percentage of employees in the general U.S. workforce testing positive for fentanyl in random drug tests far exceeded those in...

September 2, 2025Drug Testing
Read more →

FDA Grants Breakthrough Device Designation for Haystack MRD Circulating Tumor DNA Test from Quest Diagnostics

DGX

SECAUCUS, N.J., Aug. 25, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the company's Haystack MRD® test for...

Quest Diagnostics to Speak at the Baird 2025 Global Healthcare Conference

DGX

SECAUCUS, N.J., Aug. 15, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends...

Quest Diagnostics Declares Quarterly Cash Dividend

DGX

SECAUCUS, N.J., Aug. 13, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.80 per share, payable on October 20, 2025 to shareholders of record of Quest...

August 13, 2025Dividends
Read more →

Mass General Brigham Launches Two Clinical Trials to Study Haystack MRD ctDNA as Guide for Post-surgical Treatment for Two Cancer Types

DGX

SECAUCUS, N.J. and BOSTON, Aug. 7, 2025 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, today announced a research collaboration with Mass General Brigham investigators at Massachusetts Eye and Ear and Massachusetts General Hospital, world-renowned centers for...

Quest Diagnostics Collaborates With MD Anderson To Develop Multi-Cancer Stratification Blood Test

DGX

June 10, 2025
Read more →

Here's How Much You Would Have Made Owning Quest Diagnostics Stock In The Last 5 Years

DGX

May 30, 2025
Read more →

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

DGX

May 16, 2025
Read more →

JP Morgan Maintains Neutral on Quest Diagnostics, Raises Price Target to $190

DGX

May 6, 2025
Read more →

Piper Sandler Maintains Neutral on Quest Diagnostics, Raises Price Target to $200

DGX

April 28, 2025
Read more →

Here's How Much You Would Have Made Owning Quest Diagnostics Stock In The Last 5 Years

DGX

April 24, 2025
Read more →

These Analysts Boost Their Forecasts On Quest Diagnostics After Better-Than-Expected Q1 Earnings

DGX

April 23, 2025
Read more →

Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $190

DGX

April 23, 2025
Read more →

Barclays Maintains Equal-Weight on Quest Diagnostics, Raises Price Target to $185

DGX

April 23, 2025
Read more →

A Glimpse Into The Expert Outlook On Quest Diagnostics Through 12 Analysts

DGX

April 23, 2025
Read more →

Evercore ISI Group Maintains In-Line on Quest Diagnostics, Raises Price Target to $180

DGX

April 23, 2025
Read more →

Baird Maintains Outperform on Quest Diagnostics, Raises Price Target to $194

DGX

April 23, 2025
Read more →

Quest Diagnostics Revenue Rebound, Strategic Moves Fuel Outlook Confidence

DGX

Quest Diagnostics Q1 2025 revenue rose to $2.65 billion with EPS of $2.21, exceeding expectations; full-year guidance for sales and EPS reaffirmed.

April 22, 2025
Read more →

Quest Diagnostics Reaffirms 2025 Guidance For Revenue Of $10.70B-$10.85B (Vs. Cons. Of $10.78B), Adjusted EPS Of $9.55-$9.80 (Vs. Cons. Of $9.68)

DGX

April 22, 2025
Read more →

Quest Diagnostics Q1 2025 Adj EPS $2.21 Beats $2.15 Estimate, Sales $2.65B Beat $2.63B Estimate

DGX

April 22, 2025
Read more →

Examining the Future: Quest Diagnostics's Earnings Outlook

DGX

April 21, 2025
Read more →

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

DGX

April 18, 2025
Read more →

Peering Into Quest Diagnostics's Recent Short Interest

DGX

April 16, 2025
Read more →

Mizuho Maintains Outperform on Quest Diagnostics, Raises Price Target to $189

DGX

April 9, 2025
Read more →

Quest Diagnostics Announced The Launch Of A New Laboratory Blood Test Designed To Help Physicians Confirm Amyloid Brain Pathology Due To Alzheimer's Disease In Patients With Mild Cognitive Impairment Or Dementia

DGX

April 9, 2025
Read more →

Redburn Atlantic Initiates Coverage On Quest Diagnostics with Buy Rating, Announces Price Target of $195

DGX

April 2, 2025
Read more →

Quest Diagnostics Launches New HPV Screening Solution To Enhance Cervical Cancer Risk Detection

DGX

April 2, 2025
Read more →

What 9 Analyst Ratings Have To Say About Quest Diagnostics

DGX

March 20, 2025
Read more →

Baird Maintains Outperform on Quest Diagnostics, Raises Price Target to $191

DGX

March 20, 2025
Read more →

Quest Diagnostics Now Expects Worse-than-anticipated Weather To Create A Headwind To Revenue Of Around $25M And To EPS Of About $0.10 In The First Quarter Of 2025

DGX

March 19, 2025
Read more →

Quest Diagnostics Reaffirmed 2025 Guidance For Revenue Of $10.70B-$10.85B (Vs. Cons. Of $10.769B), Adjusted EPS Of $9.55-$9.80 (Vs. Cons. Of $9.71)

DGX

March 19, 2025
Read more →

Quest Diagnostics Provides Long-term Outlook Beyond 2025: Sees Revenues Compound Annual Growth Rate (CAGR) Of 4%-5%, Adjusted EPS Growth At 7%-9%

DGX

March 19, 2025
Read more →

Quest Diagnostics And Google Cloud Collaborate To Streamline Data And Personalize Customer Experiences Using Generative AI

DGX

March 18, 2025
Read more →

The Analyst Verdict: Quest Diagnostics In The Eyes Of 11 Experts

DGX

March 4, 2025
Read more →

Citigroup Downgrades Quest Diagnostics to Neutral, Maintains Price Target to $185

DGX

March 4, 2025
Read more →

Quest Diagnostics Acquires Select Assets Of Fresenius's Spectra Laboratories For Dialysis Testing Services In U.S., Terms Not Disclosed

DGX

February 24, 2025
Read more →

Grail Shares Spiked Wednesday: What's Going On?

DGX

Grail shares are trading higher Wednesday after the company announced a new collaboration with Quest Diagnostics aimed at improving provider access to its Galleri multi-cancer early detection test.

February 12, 2025
Read more →

GRAIL And Quest Diagnostics Provide GRAIL's Galleri Multi-Cancer Early Detection Test Through The Quest Diagnostics Test Ordering System

DGX

February 12, 2025
Read more →

Mainz Biomed Forms Agreement With Quest Diagnostics To Support Commercialization Of Mainz Biomed's NextGen Screening Test For Colorectal Cancer

DGX

December 19, 2024
Read more →

Quest Becomes Exclusive Validator For Results From The Hound Cannabis Breathalyzer

DGX

Hound Labs, creator of the Hound Cannabis Breathalyzer, entered into an agreement with Quest Diagnostics (NYSE: DGX), a provider of diagnostic information services.

September 14, 2022
Read more →

Morgan Stanley Maintains Equal-Weight on Quest Diagnostics, Lowers Price Target to $142

DGX

May 3, 2022
Read more →